EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV

Erick De La Torre-Tarazona iD, Alba González-Robles, Almudena Cascajero, Paloma Jiménez, José María Miró, Sonsoles Sánchez-Palomino, José Alcamí, Maria José Buzón, Javier García-Pérez iD, Hospital Clinic HIV Investigators

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Erick De La Torre-Tarazona und 9 weiteren Autor:innen. Beteiligte Einrichtung: AIDS Immunopathology Unit, National Center of Microbiology (CNM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Hauptthemen laut MEDLINE: COVID-19, Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The presence of neutralizing antibodies (NAbs) is a major correlate of protection for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Thus, different in vitro pseudoviruses‐based assays have been described to detect NAbs against SARS‐CoV‐2. However, the determination of NAbs against SARS‐CoV‐2 in people living with HIV (PLWH) through HIV‐based pseudoparticles could be influenced by cross‐neutralization activity or treatment, impeding accurate titration of NAbs. Two assays were compared using replication‐defective HIV or VSV‐based particles pseudotyped with SARS‐CoV‐2 spike to measure NAbs in COVID‐19‐recovered and COVID‐19‐naïve PLWH. The assay based on HIV‐pseudoparticles displayed neutralization activity in all COVID‐19‐recovered PLWH with a median neutralizing titer 50 (NT50) of 1417.0 (interquartile range [IQR]: 450.3−3284.0), but also in 67% of COVID‐19‐naïve PLWH (NT50: 631.5, IQR: 16.0−1535.0). Regarding VSV‐pseudoparticles system, no neutralization was observed in COVID‐19‐naïve PLWH as expected, whereas in comparison with HIV‐pseudoparticles assay lower neutralization titers were measured in 75% COVID‐19‐recovered PLWH (NT50: 100.5; IQR: 20.5−1353.0). Treatment with integrase inhibitors was associated with inaccurate increase in neutralization titers when HIV‐based pseudoparticles were used. IgG purification and consequent elimination of drugs from samples avoided the interference with retroviral cycle and corrected the lack of specificity observed in HIV‐pseudotyped assay. This study shows methodological alternatives based on pseudoviruses systems to determine specific SARS‐CoV‐2 neutralization titers in PLWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Anti-HIV AgentsHIV InfectionsHumansSARS-CoV-2Antibodies, ViralIntegrase InhibitorsSpike Glycoprotein, CoronavirusAntibodies, Neutralizing

Stichwörter der Autor:innen

HIV-1SARS-CoV-2neutralizationpseudoviruses

Substanzen

Antibodies, ViralIntegrase InhibitorsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAnti-HIV Agentsspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • AIDS Immunopathology Unit, National Center of Microbiology (CNM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Infectious Diseases Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Instituto de Salud Carlos III, CIBER de Enfermedades Infecciosas, CIBERINFEC, Majadahonda, Spain.
  • Infectious Diseases Department, Hospital Universitario Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • HIV Unit, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

ORCID-Profile: Erick De La Torre-Tarazona, Javier García-Pérez

Zitieren

APA

De La Torre-Tarazona, E., González-Robles, A., Cascajero, A., Jiménez, P., Miró, J. M., Sánchez-Palomino, S., Alcamí, J., Buzón, M. J., García-Pérez, J., & Hospital Clinic HIV Investigators (2023). Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV. Journal of Medical Virology. https://doi.org/10.1002/jmv.28543

Vancouver

De La Torre-Tarazona E, González-Robles A, Cascajero A, Jiménez P, Miró JM, Sánchez-Palomino S, et al. Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV. Journal of Medical Virology. 2023. doi:10.1002/jmv.28543

BibTeX
@article{DeLaTorreTarazona2023,
  author = {De La Torre-Tarazona, Erick and González-Robles, Alba and Cascajero, Almudena and Jiménez, Paloma and Miró, José María and Sánchez-Palomino, Sonsoles and Alcamí, José and Buzón, Maria José and García-Pérez, Javier and Hospital Clinic HIV Investigators, Hospital Clinic HIV Investigators},
  title = {Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28543}
}
Kostenlos starten →